

27th July, 2016

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

✓ The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Submission / Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, (“SEBI Regulations”) of Financial Results (Standalone and Consolidated) for the quarter ended on 30th June, 2016.

In continuation to our letter dated 11th July, 2016 intimating about the Board meeting to be held on Wednesday, 27th July, 2016, we would like to inform that the Board meeting commenced at 03:00 pm and concluded at 06:00 pm, and it considered and approved the following:

1. Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results alongwith the limited review report of the Company for the quarter ended on 30th June, 2016 as per Regulation 33 of SEBI Regulations.

In terms of Regulation 47 of the SEBI Regulations, the Company will publish Unaudited Consolidated Financial Results for the quarter ended on 30th June, 2016. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com.


2. Press Release on Financial Results including performance highlights as being submitted to the media.

The above is enclosed herewith for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above